Fundraising FoxSatsuma Pharmaceuticals
South San Francisco, US · Founded 2016 · Delaware corporation · 13 known investors
Find your way into Satsuma Pharmaceuticals
Sign up to see every warm intro you have to Satsuma Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Satsuma Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101). The company's SMART (Simple MucoAdhesive Release Technology) drug-delivery platform aims to address efficacy and administration limitations of existing migraine treatment formulations.
Founders & leadership
Satsuma Pharmaceuticals was founded in 2016 by John Kollins.
Board
Investors · 13
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Vivo Capital's portfolio page · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 6
Funding
SEC filings, press & company announcements$12.1M disclosed across 1 of 2 rounds · 2016–2019
- Undisclosed amountSeries B preferred stock financingApr 2019
Wellington Management Company (lead), CAM Capital, Cormorant, Eventide Asset Management, Lumira Ventures, Osage University Partners, RA Capital Management, SBI Investment, Shin Nippon Biomedical Laboratories, Surveyor, TPG Biotech
Source ↗
▶$12.1MraisedFeb 2018 · 4 investors · PharmaceuticalsRule 506(b)
- Heath LukatchDirector
- John KollinsExecutive Officer, Director
- Michael RiebeDirector
- Rajeev ShahDirector
- Tadayoshi IwashimaExecutive Officer
- Thomas KingDirector
- Offering amount
- $12.3M
- Amount sold
- $12.1M
- Minimum investment
- $1
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Satsuma Pharmaceuticals.
In the news
Frequently asked questions
- What does Satsuma Pharmaceuticals do?
- Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101). The company's SMART (Simple MucoAdhesive Release Technology) drug-delivery platform aims to address efficacy and administration limitations of existing migraine treatment formulations.
- Who founded Satsuma Pharmaceuticals?
- Satsuma Pharmaceuticals was founded by John Kollins in 2016.
- Who are Satsuma Pharmaceuticals's investors?
- Satsuma Pharmaceuticals's investors include OUP (Osage University Partners), Vivo Capital, Wellington Management, Lumira Ventures, RA Capital, Red Tree Venture, SBI Investment.
- How much funding has Satsuma Pharmaceuticals raised?
- Satsuma Pharmaceuticals has disclosed $12.1M raised across 1 of its 2 known rounds.
- Where is Satsuma Pharmaceuticals headquartered?
- Satsuma Pharmaceuticals is headquartered in South San Francisco, US.